Sirolimus therapy for a cGVHD murine model with scleroderma by up-regulating Tregs

XING Chen,HOU Chun-mei,LI Xin-ying,CHEN Guo-jiang,HAN Gen-cheng,FENG Jian-nan,SHEN Bei-fen,LI Yan,XIAO He
DOI: https://doi.org/10.3969/j.issn.1674-9960.2012.03.004
2012-01-01
Abstract:Objective To determine the therapeutic efficiency of sirolimus(Rapamycin) in a murine cGVHD model characterized by collagen deposition in skin.Methods Female BALB/c mice transplanted with male B10.D2 bone marrow and spleen cell mixture were used to construct a murine cGVHD model with scleroderma.The allogenic transplantation mice were randomly divided into two groups.The experimental group was treated with sirolimus by oral administration while the control group was administered with olive oil.Meanwhile,syngenic transplantation group was transplanted with bone marrow and spleen cell mixture from BALB/c mice.The body mass changes were recorded every day.Back skin was depilated and harvested for pathological analysis and RNA isolation.Changes in the gene expression level were analyzed by real-time PCR.And the proportion of CD4+CD25+FOXP3+Tregs in the peripheral blood and spleen was determined by flow cytometric analyses.Results The body mass of recipient mice treated by sirolimus gradually returned to normal like the syngenic group mice,whereas the vehicle treated control group mice maintained body mass loss till death.Histological analysis by H&E staining revealed that the skin specimen from the control group mice exhibited skin thickening,collagen deposition and mononuclear cell infiltration.In contrast,no obvious skin lesions were observed in sections from sirolimus treated group mice.Furthermore,the transcript levels of cutaneous RANTES,collagen Ⅰ,TGF-β1 and MCP-1 were demonstrated to be down-regulated in mice with sirolimus treatment compared with those in mice treated by olive oil.The proportion of the peripheral CD4+CD25+FOXP3+Tregs was significantly increased in mice exposed to sirolimus treatment compared to that in mice with vehicle treatment.Conclusion Sirolimus treatment can inhibit the activation of effective cells and infiltration of mononuclear cells in the skin through up-regulation of peripheral CD4+CD25+FOXP3+Tregs,thus ameliorating the disease symptoms and improving the life quality of mice.
What problem does this paper attempt to address?